Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2011-02-25 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
对外投资管理制度（2011年2月）
Governance Information Classification · 95% confidence The document is titled '对外投资管理制度' which translates to 'External Investment Management System' and details the company's policies, procedures, and organizational structure for managing external investments. It includes sections on investment approval authority, decision-making bodies, financial management, auditing, and compliance with laws and regulations. The content is a governance and procedural manual rather than a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it a notice or announcement of a report. The document is a detailed internal governance document related to investment management practices and policies. Therefore, it fits best under Governance Information (CGR).
2011-02-25 Chinese
2010年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '北京双鹭药业股份公司 2010 年度财务决算报告' which translates to 'Beijing SL Pharmaceutical Co., Ltd. 2010 Annual Financial Settlement Report'. It contains detailed financial data for the full year 2010, including total assets, liabilities, net assets, revenue, profit, cash flow, and comparative figures from 2009. The document includes comprehensive financial statements and analysis of the company's financial position and operating results for the entire fiscal year. The length is 2449 characters, which is sufficient to contain substantive financial data rather than just an announcement. The content matches the description of an Annual Report (10-K) as it covers the full fiscal year and provides detailed financial performance and position information. Therefore, the document should be classified as an Annual Report (10-K). FY 2010
2011-02-25 Chinese
2010年度证券投资专项说明
Audit Report / Information Classification · 90% confidence The document is titled '2010年度证券投资专项说明' which translates to '2010 Annual Securities Investment Special Explanation'. It details the company's securities investment activities during the year 2010, including investment amounts, securities held, gains and losses, and internal control measures. It includes tables of securities holdings, investment amounts, and fair value changes. The document also contains independent directors' opinions on the securities investment activities and compliance with internal control policies. The content is a detailed report on the company's securities investment activities for the year 2010, but it is not a full annual report (10-K) or an interim/quarterly report (IR). It is a specialized report focusing on securities investment activities and internal controls for that year. The document length is 2593 characters, which is relatively short but contains substantive financial data and analysis specific to securities investment. It is not an announcement or a certification but a standalone report on securities investment. Therefore, the best fitting category is 'Audit Report / Information (AR)' as it relates to a specific audit or review of securities investment activities and internal controls, excluding full annual reports. FY 2010
2011-02-25 Chinese
第四届董事会第十五次临时会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a board meeting of Beijing Shuanglu Pharmaceutical Co., Ltd. It details decisions such as the establishment of a wholly-owned subsidiary, investment in another company, and amendments to the company's articles of association. The document includes voting results and procedural compliance statements. It does not contain financial statements or detailed financial performance data, nor is it a transcript or presentation. It is clearly a Board/Management Information announcement regarding board meeting resolutions and management decisions. Therefore, the appropriate classification is MANG (Board/Management Information). The document length is 1877 characters, consistent with a typical board meeting resolution announcement rather than a full report.
2010-12-15 Chinese
对外投资公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding an external investment of 10 million RMB into Jiangyin Changfeng Pharmaceutical Technology Co., Ltd. It details the investment amount, purpose, risks, and impact on the company. The document includes board meeting resolutions and independent director opinions approving the investment. There is no financial statement or detailed financial report included, nor is it a transcript, audit, or regulatory filing. The content is focused on a capital investment transaction and related corporate governance approvals. This fits the category of Capital/Financing Update (CAP), as it reports on a financing activity (investment in another company). The document length is 3383 characters, which is sufficient for an announcement but not a full financial report. Therefore, the classification is CAP with high confidence.
2010-12-15 Chinese
独立董事关于对外投资的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on an external investment decision by the company. It discusses the board meeting approval of an investment proposal and provides an independent opinion on the fairness, legality, and strategic rationale of the investment. There are no financial statements, no quarterly or annual financial data, no earnings highlights, no voting results, and no regulatory certifications. The document is a formal opinion related to corporate governance and board oversight on a specific transaction. This fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management matters.
2010-12-15 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.